onivyde
onivyde: developed by 1 company · 1 clinical trial tracked.
onivyde evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could onivyde → MACK affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| MERRIMACK PHARMACEUTICALS INC (MACK) metastatic adenocarcinoma of the pancreas | Approved |
Clinical Trials (1)
A Randomized Phase I/II Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing Sarcoma
Primary endpoint: Phase I:To determine the recommended phase 2 doses (RP2Ds) of Onivyde combined with talazoparib (Arm A) and Onivyde combined with temozolomide (Arm B) administered to children, adolescents and young adults with refractory or recurrent solid malignancies.
Frequently asked questions
Who is developing onivyde?
onivyde is being developed by MERRIMACK PHARMACEUTICALS INC.
How many clinical trials involve onivyde?
BioSniper tracks 1 clinical trial involving onivyde.